Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Biocogniv Inc
Profile last edited on: 5/5/2021      CAGE: 8EXH5      UEI: DR19LY8GPNW1

Business Identifier: AI-powered clinical software tools for hospitals
Year Founded
2019
First Award
2020
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

50 Lakeside Avenue
Burlington, VT 05401
   (802) 349-1935
   contact@biocogniv.com
   www.biocogniv.com
Location: Single
Congr. District: 00
County: Chittenden

Public Profile

Biocogniv uses artificial intelligence to assist health care workers and the healthcare system with tools and information. One of the firm's primary products is ClinOS, a cloud-based platform that delivers real-time analysis of clinical data to healthcare workers. The firm also has developed a software solution for Covid-19 detection that uses a blood sample and can provide hospitals with a quick and affordable test to identify which patients are most likely infected with the virus and streamline those patients for further testing.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$509,630
Phase II Dollars
$0
Total Awarded
$509,630

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $299,749
Project Title: Development of a Novel Diagnostic Test for Pulmonary Embolism Based on Artificial Intelligence and Spectral Analysis of Blood
2020 1 NSF $209,881
Project Title: Development of a Novel Diagnostic Test for Pulmonary Embolism Based on Artificial Intelligence and Spectral Analysis of Blood

Key People / Management

  Artur Adib -- CEO

  Christina Cramer -- Business Operations

  George Hauser -- Chief Science Officer

  John Houston -- CTO

  Tanya Kanigan -- COO

  Peter Toshev -- Data Scientist

Company News

Dec 10 2020
Study Details First Artificial Intelligence Tool to Help Laboratories Rule-Out COVID-19
Dec 09 2020
Vermont company creates software that analyzes bloodwork to determine COVID-19 status